Mixed COPD Results for Regeneron, Sanofi Drug Cloud Approval Chances

Regeneron, Sanofi slump after late-stage trials for “smoker’s lung” drug disappoint

The drug is seen as a potential successor to Dupixent, the companies’ jointly marketed blockbuster drug that treats inflammatory conditions like COPD.

Mixed COPD results for Regeneron, Sanofi drug cloud approval chances

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner companies.

Next-gen COPD drug from Sanofi, Regeneron shows mixed results in Phase 3 trials

The drug led to a reduction in exacerbations in one study, but missed the mark in another. The companies said they are reviewing the data.

Regeneron Pharmaceuticals actions collapse at least four years after announcing a failed clinical trial - World Stock Market

Regeneron Pharmaceuticals (REGN) loses 18.89% today, reaching minimums not seen since May 6, 2021 in 485.00 $. The Aerify-2 study did not reach the criteria to demonstrate the efficacy of ITEPEKIBAM in patients with lung damage. The titles of Regeneron Pharmaceuticals (REGN) marked a maximum of the day in $ 519.78, finding buyers who dragged the price of the share at minimum not seen since May 6, 2021 in 485.00 $. Currently, REGN operates at $ 4…

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, leaving the partners to patch together a path forward.